Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 10/20 | 0.67 |
| ▸ | RAB9A | P51151 | 9/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.67 |
| ▸ | PKM | P14618 | 4/20 | 0.67 |
| ▸ | MAOB | P27338 | 1/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | SCD | O00767 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29776932 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23566380 | 0.86 | NPC1 (0.75) | CYP3A4LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL204726 | 0.84 | NPC1 (0.73) | CYP3A4LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9154906 | 0.83 | CYP3A4 (0.71) | CYP3A4LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7788764 | 0.83 | LMNA (0.71) | CYP3A4LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12020635 | 0.83 | LMNA (0.71) | CYP3A4LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL707871 | 0.83 | CYP3A4 (0.71) | CYP3A4LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2379989 | 0.83 | CYP3A4 (0.71) | CYP3A4LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28800545 | 0.83 | CYP3A4 (0.71) | CYP3A4LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30968980 | 0.83 | LMNA (1.00) | CYP3A4LMNANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024128568-A1 | BENZIMIDAZOLYLUREA DERIVATIVE AND PHARMACEUTICAL USE THEREOF | 경북대학교 산학협력단 | 2024-06-20 | — | — | WO | claimed |
| CN-112830897-A | Ureido-containing benzimidazole derivative and preparation method and application thereof | 石家庄以岭药业股份有限公司 | 2021-05-25 | — | — | CN | claimed |
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | claimed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | claimed |
| US-20130317222-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-1-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL]-1H-BENZIMIDAZOL-2-YL]UREA | VERTEX PHARMACEUTICALS INCORPORATED | 2013-11-28 | — | — | US | claimed |
| EP-2663558-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-{1-HYDROXY-1-METHYL-ETHYL}PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL}-1H-BENZIMIDAZOL-2-YL]UREA | Vertex Pharmaceuticals Incorporated (US) | 2013-11-20 | — | — | EP | claimed |
| CN-103384666-A | Solid forms of gyrase inhibitor (R)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea | VERTEX PHARMA | 2013-11-06 | — | — | CN | claimed |
| US-8481552-B2 | Solid forms of gyrase inhibitor (R)-1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-YL]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-YL]urea | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | claimed |
| US-20120184741-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | claimed |
| WO-2012097270-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-{1-HYDROXY-1-METHYL-ETHYL}PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL}-1H-BENZIMIDAZOL-2-YL]UREA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | WO | claimed |
| EP-2005169-A2 | USE OF ADDITIVES FOR THE REDUCTION OF NON-SPECIFIC BINDING IN ASSAYS | AOKIN AG (DE) | 2008-12-24 | — | — | EP | claimed |
| EP-2005170-A1 | USE OF ADDITIVES TO LOWER THE RATE OF A BINDING REACTION | AOKIN AG (DE) | 2008-12-24 | — | — | EP | claimed |
| WO-2007111851-A1 | USE OF ADDITIVES TO LOWER THE RATE OF A BINDING REACTION | AOKIN AG (DE) | 2007-10-04 | — | — | WO | claimed |
| WO-2007111847-A2 | USE OF ADDITIVES FOR THE REDUCTION OF NON-SPECIFIC BINDING IN ASSAYS | AOKIN AG (DE) | 2007-10-04 | — | — | WO | claimed |
| EP-1363625-A4 | COMBINATIONS OF DRUGS (E.G., A BENZIMIDAZOLE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS | COMBINATORX INC (US) | 2004-07-14 | — | — | EP | claimed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| EP-1363625-A1 | COMBINATIONS OF DRUGS (E.G., A BENZIMIDAZOLE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS | Combinatorx, Incorporated (US) | 2003-11-26 | — | — | EP | claimed |
| US-20020165261-A1 | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders | ZALICUS INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002058697-A1 | COMBINATIONS OF DRUGS (E.G., A BENZIMIDAZOLE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS | COMBINATORX, INCORPORATED (US) | 2002-08-01 | — | — | WO | claimed |
| US-5527711-A | Method and reagents for binding chemical analytes to a substrate surface, and related analytical devices and diagnostic techniques | HEWLETT PACKARD COMPANY (US) | 1996-06-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317222-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-1-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL]-1H-BENZIMIDAZOL-2-YL]UREA | TOP1, TOP2A, TOP2B | CYP3A4 177/4885LMNA 1793/4885NPC1 3854/4885 |
| US-20020165261-A1 | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders | DHFR, DPYD, VHL | CYP3A4 27/4885LMNA 2776/4885NPC1 2404/4885 |
| US-20120184741-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA | TOP1, TOP2A, TOP2B | CYP3A4 169/4885LMNA 1827/4885NPC1 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.